CD274 and cancer: The receptor protein PD-1 (CD279) and its ligand PD-L1 (CD274) have attracted much attention due to the discovery of clinically useful anti-cancer antibodies or drugs such as pembrolizumab that inhibit their interaction or bind to one or the other of the two proteins [106,107,108].